BioSpace News Archive

Karus Therapeutics Ltd, a clinical-stage biopharmaceutical company developing precision medicines for cancer, announces that new data will be presented from its KA2237 Phase I study at the ASH Annual Meeting & Exposition in Orlando, Florida, 9 December 2019.

Arrowhead Pharmaceuticals Inc. announced the pricing of an underwritten public offering of 4,000,000 shares of its common stock, offered at a price of $58.00 per share, before underwriting discounts.

APR Applied Pharma Research sa (“APR”), the Swiss pharma company focused in niche and rare therapeutic areas, announces that the US Food and Drug Administration (the “FDA”) has granted Orphan Drug Designation for its investigational drug code-named APR-TD011 for treatment of Epidermolysis Bullosa (“EB”).

Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that Hella Kohlhof, Ph.D., Chief Scientific Officer of Immunic, will present data on IMU-856, for the first time, at today’s IBD Innovate: Product Development for Crohn’s and Colitis conference in New York, hosted by the Crohn’s and Colitis Foundation.

Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for damage or transection to peripheral nerves, today announced Jessica de Paz has been selected to ride on the 2020 Donate Life Rose Parade float that will be featured in the annual Tournament of Roses® parade.

As we head into cold and flu season once again, Exergen Corporation, maker of the TemporalScanner thermometer, has created an educational video to help people understand how to tell if they have a cold or the flu.

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Company management will present at the 12th Annual LD Micro Main Event being held December 10-12, 2019, in Bel-Air, Calif.

MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new development and commercialization agreement.

AVEO Oncology (NASDAQ: AVEO) today announced that previously reported data from its Phase 3 TIVO-3 study were published in The Lancet Oncology.

Nanomix announced today that the company has received CE Mark for its S1 Assay for the rapid, simultaneous detection and quantification of lactate (LAC), procalcitonin (PCT), and C-reactive protein (CRP) from human plasma specimens